X4 Pharmaceuticals (XFOR) Return on Equity (2018 - 2025)

X4 Pharmaceuticals (XFOR) has 8 years of Return on Equity data on file, last reported at 0.01% in Q4 2025.

• For the quarter ending Q4 2025, Return on Equity changed 0.0% year-over-year to 0.01%; the trailing twelve-month figure through Dec 2025 stood at 0.01% (changed 0.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
• Return on Equity for Q4 2025 stood at 0.01%, up from 0.03% in the prior quarter.
• Across five years, Return on Equity topped out at 0.01% in Q1 2025 and bottomed at 0.08% in Q2 2025.
• The 5-year median for Return on Equity is 0.01% (2023), against an average of 0.02%.
• Peak annual rise in Return on Equity reached 6 bps in 2025, while the deepest fall reached 8 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2021, then decreased by 4 bps to 0.01% in 2022, then retreated by 23 bps to 0.02% in 2023, then jumped by 46 bps to 0.01% in 2024, then soared by 30 bps to 0.01% in 2025.
• The last three Return on Equity figures came in at 0.01% (Q4 2025), 0.03% (Q3 2025), and 0.08% (Q2 2025), per Business Quant data.

Peer Comparison